Skin-associated lymphoid tissue (SALT)-related B-cell lymphoma (primary cutaneous B-cell lymphoma). A concept and a clinicopathologic entity

Giannotti, B.

doi:10.1001/archderm.129.3.353

Cited by 22 publications

(8 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, PCFCL resemble nodal follicular lymphomas, in that both usually express BCL-6 and have similar gene expression profiles [46]. Furthermore, PCMZBCL or skin-associated lymphoid tissue lymphomas [47,48] may have a follicular architecture, so that dividing them into follicular center cell and marginal zone subtypes may not be always be possible. Thus, it is evident that the precise histogenesis and pathogenesis of PCBCL need to be better clarified, both to improve our understanding of the disease process and to permit optimal selection of new therapies.…”

Section: Discussionmentioning

confidence: 99%

Cutaneous B-cell lymphoma responds to rituximab: A report of five cases and a review of the literature

Gitelson

Al‐Saleem

Millenson³

et al. 2006

Leukemia & Lymphoma

View full text Add to dashboard Cite

Optimal treatment of cutaneous B-cell lymphoma (CBCL) is yet to be established. We treated five patients, each with either extensive lesions, severe comorbidities or who refused treatment with radiation therapy, with rituximab given as a single agent for four weekly intravenous infusions of 375 mg/m2. Maintenance therapy, if initiated, was given at 375 mg/m2 once every 2 - 3 months. Objective clinical responses occurred in all five patients. Three patients have ongoing complete clinical remissions with a median follow-up of 17, 19 and 39 months post achievement of complete remission. One patient died at age 87 years from a non-related cause after 5.5 years of complete remission. One patient received local radiotherapy to a solitary cutaneous site of large-cell lymphoma that developed after 3 years in remission from the low-grade CBCL; no recurrences of either grade CBCL have yet occurred. Treatment was well tolerated. Rituximab is safe and effective in treating of CBCL, either primary CBCL or low-grade lymphomas with relapses limited to the skin. Rituximab appears to present an attractive alternative when radiation therapy is contraindicated or unwanted. Additional collaborative studies are needed to assess the role of rituximab in various clinicopathologic presentations of CBCL.

show abstract

Section: Discussionmentioning

confidence: 99%

Cutaneous B-cell lymphoma responds to rituximab: A report of five cases and a review of the literature

Gitelson

Al‐Saleem

Millenson³

et al. 2006

Leukemia & Lymphoma

View full text Add to dashboard Cite

show abstract

“…PCBCLs are a peculiar group of extranodal B‐cell lymphomas arising in a site (the skin) which is physiologically devoid of organized lymphoid tissue. The formation of skin‐associated lymphoid tissue (SALT) can still be induced in particular conditions and SALT is considered to be the background from which some cases of PCBCL may develop 17–19 …”

Section: Discussionmentioning

confidence: 99%

Expression of TCL1 and CD27 in primary cutaneous B‐cell lymphomas

et al. 2006

View full text Add to dashboard Cite

These findings indicate: (i) the TCL1 oncogene product is uncommonly expressed in PCBCL (20% of cases, mainly of the follicle-centre subtype); (ii) in contrast, CD27 is often expressed in PCBCL (60% of cases), mainly of the marginal-zone subtype; (iii) the coexpression of TCL1 and CD27 may be seldom observed in PCBCL (8% of cases); (iv) PCBCL does not seem to show, in terms of either TCL1 or CD27 expression, significant differences compared with its systemic counterparts.

show abstract

“…Histological subtypes of the more common non-large cell primary cutaneous B-cell lymphomas have little correlation with disease-free period, recurrence rate, or overall behaviour of the disease. [3][4][5] Diagnosis and classification of cutaneous lymphomas remains a difficult area. At this time there is no universally agreed classification system, although the World Health Organization (WHO) Classification of Tumours of the Haematopoietic and Lymphoid Tissues and the European Organization for Research and Treatment of Cancer (EORTC) classifications are the most commonly used.…”

Section: Discussionmentioning

confidence: 99%

Cutaneous B‐cell lymphoma of nails, pinna and nose treated with chlorambucil

Stanway¹,

Rademaker²,

Kennedy³

et al. 2004

Aust J Dermatology

View full text Add to dashboard Cite

An 83-year-old woman presented with primary multifocal cutaneous B-cell lymphoma, presenting as discrete nodules on the right pinna and nail-bed of the left middle finger, diffuse swelling and erythema of several other nail-beds of the fingers and toes, with associated pincer nail deformity and rhinophyma. Because of the involvement of several sites not amenable to radiotherapy, she was treated with oral cyclical chlorambucil with good result.

show abstract

Skin-associated lymphoid tissue (SALT)-related B-cell lymphoma (primary cutaneous B-cell lymphoma). A concept and a clinicopathologic entity

Cited by 22 publications

References 0 publications

Cutaneous B-cell lymphoma responds to rituximab: A report of five cases and a review of the literature

Cutaneous B-cell lymphoma responds to rituximab: A report of five cases and a review of the literature

Expression of TCL1 and CD27 in primary cutaneous B‐cell lymphomas

Cutaneous B‐cell lymphoma of nails, pinna and nose treated with chlorambucil

Contact Info

Product

Resources

About